Illumina Buys Grail Before Its Planned IPO
Illumina is acquiring Grail for $8 billion. Market watchers hate this deal… but it will fortify Illumina’s position as one of the world’s most important biotech companies for decades to come.
Bleeding Edge
The Bleeding Edge is the only free newsletter that features investing insights from editor Colin Tedards. Here, Colin will share what he's watching in the market and which stocks you'll want on your radar.
How to Invest in the “Next Amazon”
So where have all the good investments gone? Where is the chance to invest in the next Amazon? They’re still out there…
NASA Is Looking for Life on Venus
A team of researchers from the U.K. made an incredible discovery… and it’s raising the question: “Could there be life on Venus?”
The Market Is on the Verge of “Splintering”
The next two years will be brutal for companies that don’t adapt quickly to this new environment…
USPTO Upholds Broad Institute’s CRISPR Patent Rights
The USPTO granted Broad Institute’s motion for priority benefit to its early CRISPR patents. This is great news for the industry and CRISPR companies…
Is High-Flying Tesla Stock Still a Good Buy Today?
I’m very bullish on Tesla, and I believe it has a bright future ahead. But investing at these elevated “expensive” levels isn’t investing… It’s just speculation
Biotech Company Grail Announces Its Public Offering
This exciting biotechnology firm with a method to detect early stage cancer is about to IPO. We’ll keep a close eye on this pick in the coming months…